Allergan acquired Topokine Therapeutics, a clinical-stage company developing topical medicines for fat reduction. Allergan paid $85M upfront plus undisclosed success-based development and sales milestones for XAF5, a first-in-class topical agent in late-stage development for steatoblepharon (under-eye bags).